JewishTHE Georgian Volume 24, Number 4 Atlanta, Georgia MAY-JUNE 2012 FREE Taratoot exhibition featured in Airport Atrium “The Les Fleurs Photographic Collection,” by Georgia artist Barry Taratoot, is featured in the Atrium at Hartsfield-Jackson Atlanta International Airport. “The pieces in this exhibit are stunningly surreal and focus the viewer’s eye on the exquisite detail in nature’s design,” said David Vogt, Airport Art Program manager. “The con- trolled arrangement and lighting of the flowers create a dynamic composition of textures, sur- faces, and color. The rich, black background serves to emphasize each flower’s unique con- tour and many intricacies.” The exhibition included 15 framed photo- graphs, ranging in size from 30x40 inches to 4x6 feet. Apricot Asiatic Lilly Brisbane Callas Dahlia Lavender White & Yellow Orchids The images defy the viewer to believe what he or she is seeing. The soft, yet vivid, (all photos: Barry J Taratoot Photography) colors of the plants set against solid-black backgrounds look much more like paintings than photos. Taratoot selects floral subjects and then Jackie Montag is a tireless community leader positions them amid soft light and shadows to enhance their natural surfaces, colors, and pat- By Carolyn Gold Jackie grew up in Mobile, Alabama, terns. The effect is created—“without trickery and attended Wellesley College, just out- or modern technical manipulation,” the artist There is an old saying about commu- side of Boston. At a Southern Club mixer, notes—through a combination of photograph- nity leadership: “The women do all the she met Tony Montag, who was then a ic and technical skills, patience, and imagina- work, and the men get all the credit.” To graduate student in the Harvard Business tion. shatter this notion, The Jewish Georgian is School. They married and, after Tony did Each year, the Airport Art Program solic- beginning a series on women who are his military duty, returned to Atlanta. its exhibition proposals and selects eight for community leaders. Jackie was told by her mother-in-law, presentation; exhibiting artists receive an hon- We start with a very busy lady, Jackie “Montag women get involved in the orarium. In addition to the honor of being Montag. There is hardly a good cause in League of Women Voters and Families selected, Taratoot and his exhibition were fea- Atlanta that Jackie hasn’t been involved in First, a United Way agency.” tured in an article on PPA Today, the blog of or headed. At my insistence, she modestly Thus began Jackie’s life-long interest the Professional Photographers of America, began to list her past and current leader- in family issues: health, children, educa- the most influential and prestigious organiza- tion for serious professional photographers in ship and participation roles. Partway tion, and community life. She fulfilled all the United States. Google “PPA Today Barry through, I stopped her, knowing her as the the helping roles at her children’s schools. Taratoot” to locate the article. mother of four children and now the Then she volunteered at the old Egleston For more information on Barry Taratoot grandmother of 15, and asked, “Jackie, Hospital; she has had a long-time interest and his work, visit bjtphotography.net. how have you had time to breathe?” Jackie Montag See MONTAG, page 4 Embracing the The Lithuania Putting Out the At the Helm A Change of Menu The Jews of Future Internal Passport Welcome Mat The MJCCA installs Steven An unusual offering from Macon Cadranel as its new presi- the Atlanta Jewish Film On a recent visit to Atlanta, A simple document can lead Spanish-speaking soldiers Macon’s first synagogue dent. Festival, The Apple Pushers Rabbi Richard J. Jacobs, to a treasure trove of infor- and schoolchildren of all started in a rented room is a documentary about an head of the Union of mation for genealogical races and religions are above a candy store and innovative way to fight the Reform Judaism, challenged researchers. among the many visitors to grew from there. obesity epidemic. members of The Temple to The Breman Jewish Heritage think big and act boldly. & Holocaust Museum. By Mordecai Zalman By Howard Margol By Janice Rothschild Blumberg By Brian Katzowitz By Stuart Rockoff Page 22 Page 24 Page 35 See MJCCA News, page 17 Page 7 Page 30 What’s InsideWhat’s In the treatment of type 1 Gaucher disease It’s All About the Details Talk to your doctor about VPRIV. For more information, go to vpriv.com. VPRIV is available by prescription only. IndIcatIon VPRIV is a hydrolytic lysosomal glucocerebroside- specific enzyme indicated for long-term enzyme replacement therapy (ERT) for pediatric and adult patients with type 1 Gaucher disease. Important Safety InformatIon The most serious side effects seen in patients in clinical trials with VPRIV were allergic reactions. Patients who have experienced allergic reactions to VPRIV or to other enzyme replacement therapy should proceed with caution. The most common side effects observed in clinical trials in patients treated with VPRIV were infusion-related and included: headache, dizziness, low blood pressure, high blood pressure, nausea, weakness/fatigue, and fever. Generally, infusion-related reactions were mild and, in newly treated patients, occurred mostly during the first 6 months of treatment and tended to occur less frequently with time. You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch, or call 1-800-FDA-1088. Please see Brief Summary of the full Prescribing Information on reverse side for additional Important Safety Information. VPRIV® (velaglucerase alfa for injection) Rx Only BRIEF SUMMARY: Consult the Full Prescribing Information for complete product information. Less common adverse reactions affecting more than one patient (>3% in the treatment-naïve group and >2% in the patients switched from imiglucerase to VPRIV treatment) were bone pain, tachycardia, rash, INDICATIONS AND USAGE urticaria, flushing, hypertension, and hypotension. VPRIV is a hydrolytic lysosomal glucocerebroside-specific enzyme indicated for long-term enzyme replacement therapy (ERT) for pediatric and adult patients with type 1 Gaucher disease. Pediatric Patients All adult adverse reactions to VPRIV are considered relevant to pediatric patients (ages 4 to 17 years). DOSAGE AND ADMINISTRATION Adverse reactions more commonly seen in pediatric patients compared to adult patients include (>10% The recommended dose is 60 Units/kg administered every other week as a 60-minute intravenous infusion. difference): upper respiratory tract infection, rash, aPTT prolonged, and pyrexia. Patients currently being treated with imiglucerase for type 1 Gaucher disease may be switched to VPRIV. Immunogenicity Patients previously treated on a stable dose of imiglucerase are recommended to begin treatment with VPRIV As with all therapeutic proteins, there is a potential for immunogenicity. In clinical studies, at that same dose when they switch from imiglucerase to VPRIV. 1 of 54 treatment-naïve patients treated with VPRIV developed IgG class antibodies to VPRIV. In this patient, Dosage adjustments can be made based on achievement and maintenance of each patient’s the antibodies were determined to be neutralizing in an in vitro assay. No infusion-related reactions were therapeutic goals. Clinical studies have evaluated doses ranging from 15 Units/kg to 60 Units/kg reported for this patient. It is unknown if the presence of IgG antibodies to VPRIV is associated with a higher every other week. risk of infusion reactions. Patients with an immune response to other enzyme replacement therapies who are switching to VPRIV should continue to be monitored for antibodies. VPRIV should be administered under the supervision of a healthcare professional. Immunogenicity assay results are highly dependent on the sensitivity and specificity of the assay. Additionally, CONTRAINDICATIONS the observed incidence of antibody positivity in an assay may be influenced by several factors, including None. assay methodology, sample handling, timing of sample collection, concomitant medications, and underlying WARNINGS AND PRECAUTIONS disease. For these reasons, comparison of the incidence of antibodies to VPRIV with the incidence of antibodies Hypersensitivity Reactions to other products may be misleading. Hypersensitivity reactions have been reported in patients in clinical studies with VPRIV [see ADVERSE DRUG INTERACTIONS REACTIONS]. As with any intravenous protein product, hypersensitivity reactions are possible, therefore No drug-drug interaction studies have been conducted. appropriate medical support should be readily available when VPRIV is administered. If a severe reaction occurs, current medical standards for emergency treatment are to be followed. USE IN SPECIFIC POPULATIONS Pregnancy: Pregnancy Category B. Treatment with VPRIV should be approached with caution in patients who have exhibited symptoms of Reproduction studies with velaglucerase alfa have been performed in pregnant rats at intravenous hypersensitivity to the active ingredient or excipients in the drug product or to other enzyme replacement therapy. doses up to 17 mg/kg/day (102 mg/m2/day, about 1.8 times the recommended human dose of Infusion-related Reactions 60 Units/kg/day or 1.5 mg/kg/day or 55.5 mg/m2/day based on the body surface area). Reproduction Infusion-related reactions were the most commonly observed adverse reactions in patients treated with VPRIV studies have been performed in pregnant rabbits at intravenous doses up to 20 mg/kg/day in clinical studies. The most commonly observed symptoms of infusion-related reactions were: headache, (240 mg/m2/day, about 4.3 times the recommended human dose of 60 Units/kg/day based on the body dizziness, hypotension, hypertension, nausea, fatigue/asthenia, and pyrexia. Generally the infusion-related surface area). These studies did not reveal any evidence of impaired fertility or harm to the fetus due to reactions were mild and, in treatment-naïve patients, onset occurred mostly during the first 6 months of velaglucerase alfa. treatment and tended to occur less frequently with time.